Leap Therapeutics (NASDAQ:LPTX) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Leap Therapeutics (NASDAQ:LPTX) posted its quarterly earnings data on Wednesday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02, Zacks reports.

Leap Therapeutics Stock Performance

Shares of LPTX opened at $0.36 on Friday. Leap Therapeutics has a 1 year low of $0.35 and a 1 year high of $4.79. The stock has a market capitalization of $13.98 million, a P/E ratio of -0.19 and a beta of 0.35. The company’s fifty day moving average is $0.73 and its two-hundred day moving average is $2.19.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $9.00 to $1.25 in a research report on Wednesday, January 29th. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Finally, HC Wainwright reissued a “neutral” rating on shares of Leap Therapeutics in a report on Thursday.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.